366 related articles for article (PubMed ID: 15655933)
21. Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma.
Orbaugh KK
Clin J Oncol Nurs; 2004 Jun; 8(3):242-7. PubMed ID: 15208818
[TBL] [Abstract][Full Text] [Related]
22. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
[TBL] [Abstract][Full Text] [Related]
23. Pemetrexed therapy for malignant pleural mesothelioma.
Puto K; Garey JS
Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
[TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
25. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
[TBL] [Abstract][Full Text] [Related]
26. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
Hanauske AR
Lung Cancer; 2004 Aug; 45 Suppl 1():S121-4. PubMed ID: 15261444
[TBL] [Abstract][Full Text] [Related]
27. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
[TBL] [Abstract][Full Text] [Related]
28. A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.
Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Tsumori T; Kawase I
Anticancer Res; 2012 Feb; 32(2):609-13. PubMed ID: 22287752
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed in advanced colorectal cancer.
Louvet C; de Gramont A
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):56-62. PubMed ID: 15655939
[TBL] [Abstract][Full Text] [Related]
30. Pemetrexed-cisplatin combination in mesothelioma.
Reck M; Gatzemeier U
Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
[TBL] [Abstract][Full Text] [Related]
31. Alimta (pemetrexed disodium): a multitargeted antifolate for the treatment of mesothelioma.
Green MR
Lung Cancer; 2002 Nov; 38 Suppl 2():S55-7. PubMed ID: 12431831
[TBL] [Abstract][Full Text] [Related]
32. Emerging insights into the biology and therapy of malignant mesothelioma.
Vogelzang NJ
Semin Oncol; 2002 Dec; 29(6 Suppl 18):35-42. PubMed ID: 12571809
[TBL] [Abstract][Full Text] [Related]
33. Overview of phase I/II pemetrexed studies.
Hanauske AR; Dittrich C; Otero J
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):18-25. PubMed ID: 15655932
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
[TBL] [Abstract][Full Text] [Related]
35. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T
Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757
[TBL] [Abstract][Full Text] [Related]
36. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Taylor L; Ashland J; Ye Z; Monberg MJ; Obasaju CK
Clin Lung Cancer; 2005 Jul; 7(1):40-6. PubMed ID: 16098243
[TBL] [Abstract][Full Text] [Related]
37. [First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
Burgin M; Gairard-Dory A-; Mennecier B; Molard A; Beretz L; Quoix A-
Rev Pneumol Clin; 2009 Apr; 65(2):75-83. PubMed ID: 19375046
[TBL] [Abstract][Full Text] [Related]
38. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
[TBL] [Abstract][Full Text] [Related]
39. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
Ellis P; Davies AM; Evans WK; Haynes AE; Lloyd NS;
J Thorac Oncol; 2006 Jul; 1(6):591-601. PubMed ID: 17409924
[TBL] [Abstract][Full Text] [Related]
40. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Woods B; Paracha N; Scott DA; Thatcher N
Lung Cancer; 2012 Feb; 75(2):261-7. PubMed ID: 21937141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
